Rubella complications : Congenital rubella syndromes at the beginning of pregnancy accompanied by various abnormalities such as growth retardation in the womb, cataracts, glaucoma, ductus arteriosus, ventricular septal defect, and microencephalia
The vaccine is a live vaccine that produces antibodies to three viruses - mumps, measles and rubella, which cannot be inoculated during pregnancy or when the immunity is lowered.
You can be vaccinated with the same live vaccine against chickenpox, and other four-vaccines simultaneously on the same day.
MMR should be given four weeks later after the injection of other live vaccines (chickenpox, Japanese encephalitis and nasal spray flu vaccines) and if the vaccine is given within four weeks, the vaccination shall be invalid.
Pregnancy should be avoided within 28 days of injection due to the possibility of congenital rubella syndrome.
If given within 72 hours of exposure to the measles virus, may provide protection to the spread of measles. However, inoculation after exposure to rubella and mumps has no preventive effect.
12-15개월, 4-6세에 2차 접종합니다.
In case of the spread of measles, infants at the age of 6-12 months can be vaccinated, but this is not counted.
Measles : MMR gives the infants at the age of 12-15 months a 95-98% chance of being protected against measles for life. If the first dose fails to produce antibodies, more than 90% of the second dose brings an immune response.
Visibility : After inoculation, the antibody positive rate is very high at 96 - 98%, and it lasts for more than 12 years. According to the study, it is recommended to have two inoculations because of low reports of 66% on a single inoculation, and because of the increase in antibody prices on a second inoculation.
Mumps: MMR gives a 96-98% chance of being protected against measles for 12 years. Some babies reportedly develop 66% antibodies after the first vaccination and a second dose helps activate immune system, so they’ll need two doses of MMR vaccine.
Rubella : After given once at the age of 12 months, the antibody positive rate is 95% or more, and the immune function continues for at least 15 years.
5. Vaccine Type
MMR II - MSD (subject to change depending on the situation of the pharmaceutical company)
Hanaro Medical FoundationDirector: Kwon Hae RyungLicense Number : 101-82-07995TEL : +82-2-590-1111
Jongno Center5F, 1TOWER, GRAN SEOUL, 33, Jong-ro, Jongno-gu, Seoul, South KoreaFAX : +82-2-2158-7256
Gangnam Center06211 7~11F, I Tower, 326, Teheran-ro, Gangnam-gu, Seoul, South KoreaFAX : +82-2-590-1255
COYPRIGHT ⓒ 2018 HANARO Medical Foundation. ALL RIGHTS RESERVED.